These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2007-001493-91||A LARGE SIMPLE RANDOMIZED TRIAL OF COMBINED CHOLESTEROL MODIFICATION, BLOOD PRESSURING LOWERING IN MIDDLE AGED PEOPLE AT INTERMEDIATE (MODERATE) RISK.||2015-12-15||bad-data|
|Not reported||2010-024213-31||Can Vitamin D Replacement Reduce Insulin resistance In South Asians with Vitamin D Deficiency?||2014-01-08||due-trials|
|Not reported||2011-000284-27||A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Liraglutide versus a Sulphonylurea and/or Pioglitazone||2012-12-06||due-trials|
|Ongoing||2011-005545-12||Enhanced Control of Hypertension and Thrombolysis Stroke Trial||not-yet-due|
|Ongoing||2012-002422-78||Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial.||not-yet-due|
|Ongoing||2014-001992-30||A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma||not-yet-due|
|Ongoing||2014-004049-29||Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation||not-yet-due|
|Ongoing||2014-004958-34||Midazolam Measurement and Modelling using Matrix Samplers||not-yet-due|
|Ongoing||2015-002104-91||A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Canagliflozin (Invokana™) vs. standard dual therapy regimen: The ‘Can Do Ramadan’ Study||not-yet-due|
|Ongoing||2015-003259-24||The Effect of Sildenafil (REVATIO®) on Post Cardiac Surgery Acute Kidney Injury: A Randomised, Placebo-controlled Phase IIb Clinical Trial: The REVAKI-2 Trial||not-yet-due|
|Ongoing||2017-002998-20||Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)||not-yet-due|